|
1
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
La Vecchia C, Malvezzi M, Bosetti C,
Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer
mortality and incidence: A global overview. Int J Cancer.
136:2187–2195. 2015. View Article : Google Scholar
|
|
3
|
Ito Y, Kudo T, Kihara M, Takamura Y,
Kobayashi K, Miya A and Miyauchi A: Improvement of lymph node
recurrence rate, but not distant recurrence and carcinoma death
rates, in patients with papillary thyroid carcinoma after
disease-free survival for 5 years. Endocr J. 59:895–901. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown RL, de Souza JA and Cohen EE:
Thyroid cancer: Burden of illness and management of disease. J
Cancer. 2:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Durante C, Montesano T, Torlontano M,
Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R,
Trulli F, et al: Papillary thyroid cancer: Time course of
recurrences during postsurgery surveillance. J Clin Endocrinol
Metab. 98:636–642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahn D, Park JS, Sohn JH, Kim JH, Park SK,
Seo AN and Park JY: BRAFV600E mutation does not serve as a
prognostic factor in Korean patients with papillary thyroid
carcinoma. Auris Nasus Larynx. 39:198–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nikiforov YE and Nikiforova MN: Molecular
genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol.
7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
11
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li C, Lee KC, Schneider EB and Zeiger MA:
BRAF V600E mutation and its association with clinicopathological
features of papillary thyroid cancer: A meta-analysis. J Clin
Endocrinol Metab. 97:4559–4570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brzezianska E, Pastuszak-Lewandoska D,
Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E and
Lewiński A: Investigation of V600E BRAF mutation in papillary
thyroid carcinoma in the Polish population. Neuro Endocrinol Lett.
28:351–359. 2007.PubMed/NCBI
|
|
18
|
Henke LE, Pfeifer JD, Ma C, Perkins SM,
DeWees T, El-Mofty S, Moley JF, Nussenbaum B, Haughey BH, Baranski
TJ, et al: BRAF mutation is not predictive of long-term outcome in
papillary thyroid carcinoma. Cancer Med. 4:791–799. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nasirden A, Saito T, Fukumura Y, Hara K,
Akaike K, Kurisaki-Arakawa A, Asahina M, Yamashita A, Tomomasa R,
Hayashi T, et al: In Japanese patients with papillary thyroid
carcinoma, TERT promoter mutation is associated with poor
prognosis, in contrast to BRAF (V600E) mutation. Virchows Arch.
469:687–696. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alzahrani AS, Alsaadi R, Murugan AK and
Sadiq BB: TERT promoter mutations in thyroid cancer. Horm Cancer.
7:165–177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vinagre J, Almeida A, Populo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu T, Wang N, Cao J, Sofiadis A, Dinets
A, Zedenius J, Larsson C and Xu D: The age- and shorter
telomere-dependent TERT promoter mutation in follicular thyroid
cell-derived carcinomas. Oncogene. 33:4978–4984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu R and Xing M: TERT promoter mutations
in thyroid cancer. Endocr Relat Cancer. 23:R143–R155. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marques IJ, Moura MM, Cabrera R, Pinto AE,
Simoes-Pereira J, Santos C, Menezes FD, Montezuma D, Henrique R,
Rodrigues Teixeira M, et al: Identification of somatic TERT
promoter mutations in familial nonmedullary thyroid carcinomas.
Clin Endocrinol (Oxf). 87:394–399. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin L, Chen E, Dong S, Cai Y, Zhang X,
Zhou Y, Zeng R, Yang F, Pan C, Liu Y, et al: BRAF and TERT promoter
mutations in the aggressiveness of papillary thyroid carcinoma: A
study of 653 patients. Oncotarget. 7:18346–18355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G,
Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations
and their association with BRAF V600E mutation and aggressive
clinicopathological characteristics of thyroid cancer. J Clin
Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xing M, Liu R, Liu X, Murugan AK, Zhu G,
Zeiger MA, Pai S and Bishop J: BRAF V600E and TERT promoter
mutations cooperatively identify the most aggressive papillary
thyroid cancer with highest recurrence. J Clin Oncol. 32:2718–2726.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
de Biase D, Gandolfi G, Ragazzi M,
Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei G,
Durante C, et al: TERT promoter mutations in papillary thyroid
microcarcinomas. Thyroid. 25:1013–1019. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, . Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised
American thyroid association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amin MB ES, Greene FL, Byrd DR, Brookland
RK and Washington MK: AJCC Cancer Staging Manual. (8th). (New
York). Springer International. 2017. View Article : Google Scholar
|
|
33
|
Liu R, Hao S, Zhang H, Ma J, Liu X, Xu J,
Liu X, Ning J, Sun Y, Jiang L, et al: Correlation of thyroid
stimulating hormone receptor mRNA expression levels in peripheral
blood with undesirable clinicopathological features in papillary
thyroid carcinoma patients. Oncotarget. 8:74129–74138. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren H, Shen Y, Hu D, He W, Zhou J, Cao Y,
Mao Y, Dou Y, Xiong W, Xiao Q, et al: Co-existence of BRAF(V600E)
and TERT promoter mutations in papillary thyroid carcinoma is
associated with tumor aggressiveness, but not with lymph node
metastasis. Cancer Manag Res. 10:1005–1013. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun J, Zhang J, Lu J, Gao J, Ren X, Teng
L, Duan H, Lin Y, Li X, Zhang B and Liang Z: BRAF V600E and TERT
Promoter Mutations in Papillary Thyroid Carcinoma in Chinese
Patients. PLoS One. 11:e01533192016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song YS, Lim JA, Choi H, Won JK, Moon JH,
Cho SW, Lee KE, Park YJ, Yi KH, Park DJ and Seo JS: Prognostic
effects of TERT promoter mutations are enhanced by coexistence with
BRAF or RAS mutations and strengthen the risk prediction by the ATA
or TNM staging system in differentiated thyroid cancer patients.
Cancer. 122:1370–1379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsuse M, Yabuta T, Saenko V, Hirokawa M,
Nishihara E, Suzuki K, Yamashita S, Miyauchi A and Mitsutake N:
TERT promoter mutations and Ki-67 labeling index as a prognostic
marker of papillary thyroid carcinomas: Combination of two
independent factors. Sci Rep. 7:417522017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Argyropoulou M, Veskoukis AS, Karanatsiou
PM, Manolakelli A, Kostoglou-Athanassiou I, Vilaras G, Karameris A
and Liadaki K: Low Prevalence of TERT Promoter, BRAF and RAS
Mutations in Papillary Thyroid Cancer in the Greek Population.
Pathol Oncol Res. 26:347–354. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim HJ, Park HK, Byun DW, Suh K, Yoo MH,
Min YK, Kim SW and Chung JH: Iodine intake as a risk factor for
BRAF mutations in papillary thyroid cancer patients from an
iodine-replete area. Eur J Nutr. 57:809–815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Frasca F, Nucera C, Pellegriti G, Gangemi
P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et
al: BRAF(V600E) mutation and the biology of papillary thyroid
cancer. Endocr Relat Cancer. 15:191–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schulten HJ, Salama S, Al-Mansouri Z,
Alotibi R, AlGhamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H,
Al-Johari A, Huwait E, et al: BRAF mutations in thyroid tumors from
an ethnically diverse group. Hered Cancer Clin Pract. 10:102012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Elisei R, Ugolini C, Viola D, Lupi C,
Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A and Basolo F:
BRAF(V600E) mutation and outcome of patients with papillary thyroid
carcinoma: A 15-year median follow-up study. J Clin Endocrinol
Metab. 93:3943–3949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oler G and Cerutti JM: High prevalence of
BRAF mutation in a Brazilian cohort of patients with sporadic
papillary thyroid carcinomas: Correlation with more aggressive
phenotype and decreased expression of iodide-metabolizing genes.
Cancer. 115:972–980. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Elisei R, Viola D, Torregrossa L, Giannini
R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, et
al: The BRAF(V600E) mutation is an independent, poor prognostic
factor for the outcome of patients with low-risk intrathyroid
papillary thyroid carcinoma: Single-institution results from a
large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAF V600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ito Y, Yoshida H, Maruo R, Morita S,
Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, et
al: BRAF mutation in papillary thyroid carcinoma in a Japanese
population: Its lack of correlation with high-risk
clinicopathological features and disease-free survival of patients.
Endocr J. 56:89–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ,
Lee NS, Park WC, Kim JS, Jung SS and Bae JS: Is the BRAF(V600E)
mutation useful as a predictor of preoperative risk in papillary
thyroid cancer? Am J Surg. 203:436–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fugazzola L, Puxeddu E, Avenia N, Romei C,
Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S,
et al: Correlation between B-RAFV600E mutation and
clinico-pathologic parameters in papillary thyroid carcinoma: Data
from a multicentric Italian study and review of the literature.
Endocr Relat Cancer. 13:455–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Muzza M, Colombo C, Rossi S, Tosi D,
Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B, et
al: Telomerase in differentiated thyroid cancer: Promoter
mutations, expression and localization. Mol Cell Endocrinol.
399:288–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yin L, Tang Y, Yu S, Wang C, Xiao M, Wang
Y, Liu SJ, Gao L, Huang K and Jin L: The role of BRAF V600E in
reducing AUS/FLUS diagnosis in thyroid fine needle aspiration.
Endocr Pathol. 30:312–317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aubhishek Z, Wei W and Trever GB:
Targeting Oncogenic BRAF: Past, Present, and Future. Cancers
(Basel). 11:11972019. View Article : Google Scholar
|
|
52
|
Li XY, Zhang B and Lin YS: The
Interpretation of 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer. Zhonghua Er Bi Yan Hou Tou Jing Wai
Ke Za Zhi. 52:309–315. 2017.(In Chinese). PubMed/NCBI
|
